PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.25%
Similar G&A growth to GNPX's 52.68%. Walter Schloss would investigate industry cost structures.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.84%
Operating expenses growth above 1.5x GNPX's 17.95%. Michael Burry would check for inefficiency.
63.84%
Total costs growth above 1.5x GNPX's 17.95%. Michael Burry would check for inefficiency.
217.76%
Interest expense change of 217.76% while GNPX maintains costs. Bruce Berkowitz would investigate control.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
63.84%
Other expenses growth 1.25-1.5x GNPX's 46.73%. Martin Whitman would scrutinize cost items.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
88.24%
Tax expense change of 88.24% while GNPX maintains burden. Bruce Berkowitz would investigate strategy.
-88.24%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-87.91%
EPS decline while GNPX shows 34.62% growth. Joel Greenblatt would examine position.
-87.91%
Diluted EPS decline while GNPX shows 34.62% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.